Evidence map›Paper›PMID 27053113›Full record

ArticleThe Journal of biological chemistry2016

The Stability and Expression Level of Bok Are Governed by Binding to Inositol 1,4,5-Trisphosphate Receptors.

Jacqualyn J Schulman, Forrest A Wright, Xiaobing Han, Eric J Zluhan, Laura M Szczesniak, Richard J H Wojcikiewicz

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. Phosphorylation of Bok at Ser-8 blocks its ability to suppress IPCell communication and signaling : CCS · 2025
    Article
  4. Article
  5. Article
  6. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis.Nature reviews. Molecular cell biology · 2023
    Review
  7. Review
  8. Bok: real killer or bystander with non-apoptotic roles?Frontiers in cell and developmental biology · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. BOK controls apoptosis by CaCell reports · 2021
    Article
  17. Identification of the Bok Interactome Using Proximity Labeling.Frontiers in cell and developmental biology · 2021
    Article
  18. Review
  19. BAX, BAK, and BOK: A Coming of Age for the BCL-2 Family Effector Proteins.Cold Spring Harbor perspectives in biology · 2020
    Review
  20. Bcl-2-Protein Family as Modulators of IPCold Spring Harbor perspectives in biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jacqualyn J SchulmanFrom the Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York 13210.
Forrest A WrightFrom the Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York 13210.
Xiaobing HanFrom the Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York 13210.
Eric J ZluhanFrom the Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York 13210.
Laura M SzczesniakFrom the Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York 13210.
Richard J H WojcikiewiczFrom the Department of Pharmacology, SUNY Upstate Medical University, Syracuse, New York 13210 wojcikir@upstate.edu.
SUNY Upstate Medical University · US

Funding

IP3 Receptor Ubiquitination and Down-regulationR01DK049194 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI WOJCIKIEWICZ, RICHARD J H · 2000 to 2012
$3.7M
DOWN-REGULATION OF INSP3 RECEPTORSR29DK049194 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI WOJCIKIEWICZ, RICHARD J H · 1995 to 1999
–
NIDDK NIH HHS R01 DK049194NIDDK NIH HHS R29 DK049194
6 · The paper itself

Abstract

Bok is a member of the Bcl-2 protein family that governs the intrinsic apoptosis pathway, although the role that Bok plays in this pathway is unclear. We have shown previously in cultured cell lines that Bok interacts strongly with inositol 1,4,5-trisphosphate receptors (IP3Rs), suggesting that it may contribute to the structural integrity or stability of IP3R tetramers. Here we report that Bok is similarly IP3R-assocated in mouse tissues, that essentially all cellular Bok is IP3R bound, that it is the helical nature of the Bok BH4 domain, rather than specific amino acids, that mediates binding to IP3Rs, that Bok is dramatically stabilized by binding to IP3Rs, that unbound Bok is ubiquitinated and degraded by the proteasome, and that binding to IP3Rs limits the pro-apoptotic effect of overexpressed Bok. Agents that stimulate IP3R activity, apoptosis, phosphorylation, and endoplasmic reticulum stress did not trigger the dissociation of mature Bok from IP3Rs or Bok degradation, indicating that the role of proteasome-mediated Bok degradation is to destroy newly synthesized Bok that is not IP3R associated. The existence of this unexpected proteolytic mechanism that is geared toward restricting Bok to that which is bound to IP3Rs, implies that unbound Bok is deleterious to cell viability and helps explain the current uncertainty regarding the cellular role of Bok.

Indexed as

AnimalsCalciumCalcium SignalingElectrophoresis, Polyacrylamide GelHeLa CellsHumansImmunoprecipitationInositol 1,4,5-TrisphosphateInositol 1,4,5-Trisphosphate ReceptorsMiceMice, KnockoutModels, MolecularMolecular Dynamics SimulationMutationProtein BindingProtein ConformationBOK protein, humanCalciumInositol 1,4,5-TrisphosphateInositol 1,4,5-Trisphosphate ReceptorsItpr1 protein, mouseProto-Oncogene Proteins c-bcl-2apoptosisB-cell lymphoma 2 (Bcl-2) familyinositol trisphosphate receptor (InsP3R)proteasomeubiquitin

Identifiers

PMID27053113
PMCPMC4882449
OpenAlexW2319610440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.